I will be attending this years ECPC Masterclass in Munich over this weekend and then presenting at the EPOSSI 10th workshop on Rare Cancers in Brussels on Monday and Tuesday so I might not be able to access this forum until the middle of next week.
I am so pleased that Devon PCT have taken such a positive view on the reimbursement of dasatinib and nilotinib for CP and AP CML patients resistant to or intolerant of imatinib who are living the the South West. I really hope that NICE follow this decision.. I understand that their decision will be published very soon.
Leukaemia Care were the only patient group present at the appraisal on 14th October.
Although it is disappointing that we were overlooked, apparently emails never arrived for reasons that I can not quite understand, I am sure that Leukaemia Care were able to robustly represent the CML patients point of view.
I hope you all have a good and peaceful weekend.
Sandy